Latest news and press releases

AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease

Oct 9, 2025

Download Our About AviadoBio Company Overview

Download

AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease

Oct 9, 2025 | Press Releases

AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London

May 15, 2025 | Press Releases

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN

May 1, 2025 | Press Releases

Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications

Oct 8, 2024 | Press Releases

ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center

Jul 1, 2024 | Press Releases

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Apr 15, 2024 | Press Releases

AviadoBio Appoints John Isaac as Chief Scientific Officer

Dec 11, 2023 | Press Releases

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

Nov 6, 2023 | Press Releases

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

Oct 24, 2023 | Press Releases

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

Oct 10, 2023 | Press Releases

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

Feb 23, 2023 | Press Releases

AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors

Feb 1, 2023 | Press Releases

4
1
2
5

No results found.

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

Leadership Team

SCIENCE & Innovation

Find out more about our innovative gene therapies

Science & Delivery

Publications & Presentations

Programs

Our pipeline and programs reflect our mission to deliver the future of gene therapy

Retinitis Pigmentosa

Alzheimer's and other Tauopathies

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

Life at AviadoBio

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here

For General Enquiries

For Patients and Caregivers